Cass Samuel, White Michael G
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Colon Rectal Surg. 2023 Jan 25;36(2):112-119. doi: 10.1055/s-0043-1760864. eCollection 2023 Mar.
The microbiome (bacteria, viruses, and fungi) that exist within a patient's gastrointestinal tract and throughout their body have been increasingly understood to play a critical role in a variety of disease, including a number of cancer histologies. These microbial colonies are reflective of a patient's overall health state, their exposome, and germline genetics. In the case of colorectal adenocarcinoma, significant progress has been made in understanding the mechanism the microbiome plays beyond mere associations in both disease initiation and progression. Importantly, this improved understanding holds the potential to further identify the role these microbes play in colorectal cancer. We hope this improved understanding will be able to be leveraged in the future through either biomarkers or next-generation therapeutics to augment contemporary treatment algorithms through the manipulation of a patient's microbiome-whether through diet, antibiotics, prebiotics, or novel therapeutics. Here we review the role of the microbiome in the setting of patients with stage IV colorectal adenocarcinoma in both the development and progression or disease as well as response to therapeutics.
人们越来越认识到,存在于患者胃肠道及全身的微生物群(细菌、病毒和真菌)在包括多种癌症组织学类型在内的各种疾病中起着关键作用。这些微生物群落反映了患者的整体健康状况、暴露组和种系遗传学。就结直肠癌而言,在理解微生物群在疾病发生和进展中所起的作用机制方面,已取得了重大进展,而不仅仅是了解其相关性。重要的是,这种更深入的理解有可能进一步明确这些微生物在结直肠癌中所起的作用。我们希望,未来能够通过生物标志物或新一代疗法利用这种更深入的理解,通过操纵患者的微生物群(无论是通过饮食、抗生素、益生元还是新型疗法)来完善当代治疗方案。在此,我们综述微生物群在IV期结直肠癌患者疾病发生、进展以及对治疗反应中的作用。